EU’s Proposed Emergency Approval Route For Crisis-Related Products – Would It Work?
Executive Summary
The temporary emergency marketing authorization, or TEMA, would be similar to the existing conditional approval while lasting only for the duration of the health crisis. But one law firm queries whether the new mechanism would be any faster in practice.
You may also be interested in...
EMA Chief Backs Restructuring Plan & ‘Regulatory Sandbox’ Proposal
Emer Cooke told a European Parliament committee that she hoped the European Medicines Agency would be given sufficient resources to carry out its new tasks under the revision of the EU pharmaceutical legislation.
EU Pharma Reform Proposes Cuts In Regulatory Protections & Faster Drug Approval Times
Proposals for the overhaul of the EU pharmaceutical legislation will make medicines more widely available, accessible and affordable while supporting innovation and boosting the “competitiveness and attractiveness” of Europe’s pharma industry, the European Commission claims. The research-based industry thinks otherwise, saying cuts in regulatory protections will undermine R&D.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.